1834 Investment Advisors Co. Sells 4,534 Shares of Johnson & Johnson (NYSE:JNJ)

1834 Investment Advisors Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,197 shares of the company’s stock after selling 4,534 shares during the period. 1834 Investment Advisors Co.’s holdings in Johnson & Johnson were worth $7,811,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Johnson & Johnson in the first quarter worth approximately $765,000. Almanack Investment Partners LLC. boosted its stake in Johnson & Johnson by 1.3% in the first quarter. Almanack Investment Partners LLC. now owns 6,430 shares of the company’s stock worth $1,017,000 after buying an additional 80 shares in the last quarter. Lincoln National Corp boosted its stake in Johnson & Johnson by 1.4% in the first quarter. Lincoln National Corp now owns 77,322 shares of the company’s stock worth $12,231,000 after buying an additional 1,083 shares in the last quarter. Hendley & Co. Inc. boosted its stake in Johnson & Johnson by 0.3% in the first quarter. Hendley & Co. Inc. now owns 63,461 shares of the company’s stock worth $10,039,000 after buying an additional 214 shares in the last quarter. Finally, Horan Securities Inc. boosted its stake in Johnson & Johnson by 30.9% in the first quarter. Horan Securities Inc. now owns 6,483 shares of the company’s stock worth $1,026,000 after buying an additional 1,531 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. The Goldman Sachs Group decreased their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Stock Down 0.4 %

JNJ stock opened at $157.76 on Thursday. The business’s 50-day moving average price is $162.96 and its 200-day moving average price is $155.76. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market cap of $379.83 billion, a P/E ratio of 22.83, a PEG ratio of 2.81 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the firm earned $2.66 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.14%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.